2025-12-16
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
news
-
-
2025-09-25The FDA Granted Orphan Drug Designation to Biostar Pharma’s Utidelone for the Treatment of Pancreatic Cancer
-
2025-09-12First Patient Dosed in Phase II/III Multiple Region Clinical Trial (MRCT) of Utidelone Capsules as First-Line Treatment for Advanced Gastric Cancer
-
2025-09-11First Patient Dosed in Global, Multicenter Clinical Trial | Utidelone Capsule for the Treatment of Advanced Ovarian Cancer
-
2025-07-14First Patient Enrolled in Phase III Trial of Utidelone Capsule for Adjuvant Therapy in Triple-Negative Breast Cancer
-
2025-05-15Another IND Approval of International Multicenter Study | Phase II/III Clinical Trial of Utidelone Capsule for Platinum-Resistant Ovarian Cancer
-
2025-04-24Beijing Biostar To Present Multiple Clinical Research Achievements of Utidelone at ASCO 2025 with an Oral Presentation
-
2025-02-05Beijing Biostar received US FDA’s IND approval to conduct a multiple-region-clinical-trial (MRCT) of Utidelone Capsule for the first-line treatment of advanced gastric cancer
-
2024-11-14Biostar to collaborate with Baheal Medical to accelerate the commercialization process of Utidelone
-
2024-10-31Beijing Biostar successfully landed on the main board of the Hong Kong Stock Exchange, synthetic biology leads the new era of innovative drug research and development
-
2024-09-30Preliminary data released from a clinical study of Utidelone for the first-line treatment of advanced pancreatic cancer
-
2024-09-03Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule